ClinicalTrials.gg

Program

EDI-048

In Novartis's pipeline, CpPI(4)K inhibitor. Its studies are mostly in Cryptosporidiosis, led by Novartis.

Furthest: phase 2, since Nov 18, 20252 company-led studies, 1 open or runningNext primary completion: Mar 23, 2027 (phase 2)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Novartis21 open or runningphase 2since Nov 18, 2025Mar 2, 2022Mar 23, 2027phase 2 · NCT07249463
  • Named in Novartis’s own pipeline as EDI048, phase 2, as of Nov 16, 2026 (source).

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Mar 2, 2022First study: phase 1 study in Healthy VolunteersFirst studyNCT05275855 · 110 enrolled · United Kingdom
  2. Nov 18, 2025Phase 2 study in CryptosporidiosisPhase 2 reachedNCT07249463 · 80 planned · United States

Ahead

  1. Mar 23, 2027Primary completion: phase 2 study in CryptosporidiosisNCT07249463

TargetBeta

A vaccine: it acts on a pathogen, not a human gene.

“CpPI(4)K inhibitor”the company's pipeline, read by Claude · source

Studies

All 2 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07249463Cryptosporidiosis · United States2RecruitingMar 23, 202780
NCT05275855Healthy Volunteers · United Kingdom1CompletedDec 18, 2024110

How it is read

Names in the registry

  • “EDI048”, 2 entries

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.